Could laughing gas lift the fog of depression?
NCT ID NCT07262008
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether inhaling nitrous oxide (laughing gas) can reduce depression symptoms in 120 adults with treatment-resistant major depressive disorder. Participants will receive either nitrous oxide plus a placebo or oxygen plus a mild sedative, and their mood will be tracked for 12 weeks. The goal is to see if this quick, one-hour treatment can provide lasting relief.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nitrous oxide (laughing gas)
What this could lead to
If it works, this could offer a fast-acting, short-term option to ease depression symptoms in people who haven't responded to other treatments.
What could go wrong
This is still an early Phase 3 trial with only 120 people. The effect may be small or temporary, and laughing gas can cause side effects like nausea or dizziness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Michael's Hospital (Unity Health)
Toronto, Ontario, M5B 1W8, Canada
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
-
Toronto General Hospital (UHN)
Toronto, Ontario, M5G 2C4, Canada
-
Toronto Western Hospital (UHN)
Toronto, Ontario, M5T 2S8, Canada
-
Women's College Hospital
Toronto, Ontario, M5S 1B2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••